Results 51 to 60 of about 65,545 (257)

The Novel Oral Anticoagulants [PDF]

open access: yesSeminars in Thrombosis and Hemostasis, 2013
After the introduction of warfarin, long-term oral anticoagulation treatment remained unchanged for more than 50 years. Most recently, with the development and approval of new oral anticoagulants, the treatment of medical conditions that require thrombosis prophylaxis and long-term anticoagulation has become more complex.
Cristhiam M, Rojas-Hernandez   +1 more
openaire   +2 more sources

Oral Astilbin Nanogels Modulate Senescence‐Associated CD4+ T Cells and Promote Treg Induction in Aged Mice with Colitis

open access: yesAdvanced Science, EarlyView.
Fluorinated β‐glucan/pectin nanogels enable colon‐targeted oral delivery of astilbin through gastrointestinal protection, β‐glucanase‐responsive release, mucus penetration, and prolonged retention. The released astilbin attenuates senescence‐associated features of CD4+ T cells and promotes Treg responses, while the nanogel matrix modulates the gut ...
Lei Zhao   +11 more
wiley   +1 more source

Warfarin time in therapeutic range of primary healthcare patients in the Western Cape Province, South Africa

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction Warfarin therapy is the mainstay of anticoagulation treatment in South Africa and requires frequent INR monitoring due to interindividual patient variability. Time in therapeutic range (TTR) reflects the proportion of total treatment time during which INR values are within therapeutic range.
Masudah Paleker   +3 more
wiley   +1 more source

Stroke due to Left Atrial Appendage Thrombus after Pulmonary Vein Isolation despite Novel Oral Anticoagulant: A Case Report

open access: yesCase Reports in Neurology, 2021
In patients with atrial fibrillation, catheter ablation is suggested to reduce the mortality rate and is thus frequently performed. However, peri- and postprocedural thromboembolic complications as well as high recurrence rates of atrial fibrillation ...
Woon Hyung Chae   +5 more
doaj   +1 more source

Long‐acting cabotegravir and rilpivirine in people with HIV receiving chronic anticoagulation: A real‐world case series

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Background Long‐acting intramuscular cabotegravir plus rilpivirine (LA‐CAB + RPV) is an effective maintenance antiretroviral regimen for virologically suppressed people with HIV. However, its use in individuals receiving chronic anticoagulation is limited by concerns regarding intramuscular bleeding risk, and real‐world data are scarce.
Montserrat Laguno   +13 more
wiley   +1 more source

Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation

open access: yesBMC Cardiovascular Disorders, 2021
Background This study assessed the sociodemographic, functional, and clinical determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation (NVAF) attended in the internal medicine setting.
Jose María Mostaza   +5 more
doaj   +1 more source

Antithrombotic Therapy in Complex Percutaneous Coronary Intervention Patients Requiring Chronic Anticoagulation

open access: yesUS Cardiology Review, 2021
The optimal antithrombotic treatment in patients receiving oral anticoagulation undergoing percutaneous coronary intervention (PCI) has been a field of intensive research.
Despoina-Rafailia Benetou   +3 more
doaj   +1 more source

Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou   +10 more
wiley   +1 more source

The incidence of atrial fibrillation, new oral anticoagulation, stroke, and significant bleeds in patients receiving a new dual-chamber pacemaker

open access: yesInternational Journal of Cardiology: Heart & Vasculature, 2023
Background and objectives: Atrial fibrillation and flutter (AF/AFL) can be easily detected in patients who have a dual-chamber pacemaker (PM). This can result in a high detection rate of these arrhythmias especially if patients are monitored remotely and
Elias Parkkari   +4 more
doaj   +1 more source

The Mechanism of Action of Oral Anticoagulants and Its Consequences for the Practice of Oral Anticoagulation [PDF]

open access: yesHaemostasis, 2009
A short review on the discovery of the relation between vitamin K and the synthesis of clotting factors and on the development of anticoagulant therapy is given. The pro-coagulant activity induced by vitamin K resides in the postribosomal modification of N-terminal glutamic acids in γ-COOH glutamic acids.
Hemker, H.C., Frank, H.L.L.
openaire   +3 more sources

Home - About - Disclaimer - Privacy